A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Primary Objective
A double blind comparison of enzalutamide plus pembrolizumab or placebo in patients with metastatic prostate cancer.
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
Highlands Ranch Hospital
University of Colorado Hospital
Study ID
Protocol Number: 19-0493
More information available at ClinicalTrials.gov: NCT03834493
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers